StemCell Therapy

Drugs for Rheumatoid Arthritis Market has witnessed continuous growth within the past few years and is projected to grow even more throughout the forecast period (2020 2027). The analysis presents a whole assessment of the market and contains Future trends, Current Growth Factors, attentive opinions, facts, historical information, and statistically supported and trade valid market information.

The report, titled Global Drugs for Rheumatoid Arthritis Market defines and briefs readers about its products, applications, and specifications. The research lists key companies operating in the global market and also highlights the key changing trends adopted by the companies to maintain their dominance. By using SWOT analysis and Porters five force analysis tools, the strengths, weaknesses, opportunities, and threats of key companies are all mentioned in the report. All leading players in this global market are profiled with details such as product types, business overview, sales, manufacturing base, competitors, applications, and specifications.

You Can Request A Demo Version of Report Before Buying (Higher Preference For Corporate Email ID User): https://www.worldwidemarketreports.com/sample/201374

AbbVie Inc., Boehringer Ingelheim GmbH, Novartis AG, Regeneron Pharmaceuticals Inc., Pfizer Inc., Johnson & Johnsons Services Inc, Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd., Amgen Inc. of the major organizations dominating the global market.(*Note: Other Players Can be Added per Request)

1. Industry outlookThis is where youll find the current state of the Drugs for Rheumatoid Arthritis industry overall and where its headed. Relevant industry metrics like size, trends, life cycle, and projected growth included here. This report comes prepared with the data to back up your business idea. On a regional basis, the Global Drugs for Rheumatoid Arthritis market has been segmented into Asia-Pacific, North America, Europe, Latin America, and the Middle East and Africa.

2. Target marketThis target market section of study includes the following:

User persona and characteristics: It includes demographics such as age, income, and location. It lets you know what their interests and buying habits are, as well as explain the best position to meet their needs.

Market size: How big is the potential Drugs for Rheumatoid Arthritis market for your business? It brings to light the consumption in the Drugs for Rheumatoid Arthritis industry by the type and application.

3. Competitive analysisDiscover your competitors. The report lets you know what youre up against, but it also lets you spot the competitions weaknesses. Are there customers that are underserved? What can you offer that similar businesses arent offering? The competitive analysis contains the following components:

Direct competitors: What other companies are offering similar products and services? Which companies are your true competitors?

Competitor strengths and weaknesses: What is your competition good at? Where do they fall behind? Get insights to spot opportunities to excel where others are falling short.

Barriers to entry: What are the potential pitfalls of entering the Drugs for Rheumatoid Arthritis market? Whats the cost of entry? Is it prohibitively high, or easy to enter?

The window of opportunity:Does your entry into the Drugs for Rheumatoid Arthritis industry rely on time-sensitive technology? Do you need to enter early to take advantage of an emerging market?

4. ProjectionsLikewise, We offered thoughtful, not hockey-stick forecasting.

Market share:We have given the consumption behavior of users. When you know how much can your future customers spend, then only youll understand how much of the Drugs for Rheumatoid Arthritis industry you have a chance to grab, and here we came up with real stats and numbers.

Impact Analysis of COVID-19:The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into account the political, economic, social, and technological parameters.

Finally, It is one report that hasnt shied away from taking a critical look at the current status and future outlook for the consumption/sales of these products, by the end users and applications. Not forgetting the market share control and growth rate of the Drugs for Rheumatoid Arthritis Industry, per application. Most noteworthy, this market analysis will help you find market blind spots.

About WMR

Worldwide Market Reports is your one-stop repository of detailed and in-depth market research reports compiled by an extensive list of publishers from across the globe. We offer reports across virtually all domains and an exhaustive list of sub-domains under the sun. The in-depth market analysis by some of the most vastly experienced analysts provide our diverse range of clients from across all industries with vital decision making insights to plan and align their market strategies in line with current market trends.

Contact Us:

Mr. ShahWorldwide Market ReportsSeattle, WA 98154,U.S.Email: [emailprotected]

Go here to read the rest:
Drugs for Rheumatoid Arthritis Market Evolution of Key Players That Will Change Industry AbbVie Inc., Boehringer Ingelheim GmbH, Novartis AG - Daily...

Rheumatoid factor (RF) isotypes and anticitrullinated protein antibodies (ACPA) are strongly associated with future cardiovascular (CV) events, including acute coronary syndrome (ACS) and stroke, in patients with rheumatoid arthritis (RA), according to study results published in Arthritis and Rheumatology.

The study cohort included patients from the Swedish Epidemiological Investigation of RA who received a diagnosis of RA between 1996 and 2009 (N=2814). Using these cases, researchers centrally typed baseline serologic data based on the anticyclic citrullinated peptide test (anti-CCP2), 20 ACPA subspecificities, and RF isotypes. Patients were followed over a median 13-year follow-up period through the Swedish national patient register and cause of death register until the first event of ACS, stroke, CV-related mortality, or major adverse CV event (MACE). The association between each serologic marker and CV outcome was examined and adjustments were made for baseline Disease Activity Score in 28 joints (DAS28), smoking, and income level.

During the follow-up period, a total of 375 first ACS, stroke, and CV death events occurred. There was an association between anti-CCP2 positivity and risk for incident ACS (hazard ratio [HR], 1.46; 95% CI, 1.03-2.06; P =.035), stroke (HR, 1.47; 95% CI, 1.03-2.10; P =.034), and MACE (HR, 1.34; 95% CI, 1.06-1.70; P =.014). A similar nonsignificant association was found between anti-CCP2 positivity and CV death (HR, 1.48; 95% CI, 0.94-2.31; P =.087).

Immunoglobulin M (IgM) RF was associated with stroke (HR, 1.42; 95% CI, 1.01-2.01; P =.045) and MACE (HR, 1.40; 95% CI, 1.11-1.76; P =.0045). The researchers also observed a significant association between IgA RF and an increased risk for CV mortality (HR, 1.88; 95% CI, 1.22-2.88; P =.0038). After adjustment for smoking, income, and DAS28, IgA RF remained associated with CV mortality (HR, 1.61; 95% CI, 1.05-2.48). In analyses stratified by smoking status, IgA and IgG RF were associated with CV mortality and IgG and IgM RF were associated with MACE in patients who had never smoked.

Strong associations were found between all-cause mortality and anti-CCP2 positivity, anti-CCP2 level, autoantibody load, the majority of the ACPA subspecificities, and each RF isotype.

A limitation of this study was the lack of adjustment for lipid profile, family history of cardiovascular disease, physical activity, and comorbid conditions.

The researchers suggested that with regard to the risk for CV events, patients with high anti-CPP2 levels or presence of IgA or IgG RF at diagnosis are at higher risk and might benefit from closer monitoring from a cardio preventative perspective.

Disclosure: Several study authors declared affiliations with the pharmaceutical industry. Please see the original reference for a full list of authors disclosures.

Reference

Westerlind H, Rnnelid J, Hansson M, et al. Anti-citrullinated protein antibody specificities, rheumatoid factor isotypes and incident cardiovascular events in patients with rheumatoid arthritis [published online May 31, 2020]. Arthritis Rheumatol. doi:10.1002/art.41381

Read more here:
Rheumatoid Factor Isotypes, ACPAs Show Strong Associations With Future Cardiovascular Events in RA - Rheumatology Advisor

Pain and fatigue in patients with psoriatic arthritis (PsA) receiving tumor necrosis factor inhibitors (TNFis) significantly reduce health-related quality of life (HRQoL), physical function, and work productivity, according to study results published in Rheumatic and Musculoskeletal Diseases.

In this retrospective analysis of global data, researchers evaluated the incidence and severity of pain and fatigue in patients with PsA receiving TNFis, and assessed the association between pain and fatigue severity and HRQoL and work productivity.

A total of 3782 patients with PsA undergoing TNFi treatment participated in the study. Characteristics including patient demographics and comorbidities were collected by questionnaires completed by both patients and their physicians; patient-reported forms included the 3-level 5-dimension EuroQoL, the Medical Outcomes Study 36-Item Short-Form version 2 (SF-36v2), and the Work Productivity and Activity Impairment (WPAI) questionnaires.

Among the total cohort, 640 patients (43.4%) were included in the analysis who were receiving TNFis for 3 months and had completed the SF-36v2 bodily pain and vitality domains of the questionnaire. Overall, 37.7% and 45.6% of patients reported severe pain and fatigue, respectively. A greater percentage of patients who reported severe vs low or no pain and fatigue were considered to have severe and unstable/deteriorating disease by their physicians, respectively. In addition, a higher percentage of patients who reported severe vs low or no pain and fatigue had current flares. A total of 83.3% and 88.0% of patients who reported severe pain and fatigue, respectively, were considered to have stable/improving disease by their physicians; however, physicians reported that 39.8% and 45.5% of patients with severe pain and fatigue were considered to be in remission, which indicated a discordance between patient and physician assessment of pain and fatigue.

Scores across HRQoL and WPAI were significantly different across the pain and fatigue severity cohorts (P <.0001). Both HRQoL and WPAI measures were worse in patients with moderate to severe vs low pain and/or fatigue, indicating an association with greater work impairment.

Based on these findings, the investigators indicated that despite treatment with TNFis, patients with PsA experienced substantial pain and/or fatigue, which was associated with decreased HRQoL, physical function, and work productivity.

Study limitations included the potential subjectivity of physicians ratings, the variability of reporting across regions, and the inclusion of pain and fatigue data only from patients receiving TNFis.

Researchers concluded, The high burden that severe pain and/or fatigue, in spite of TNFi treatment, place on patients in terms of limited function, diminished HRQoL and reduced ability to contribute to society as part of the workforce indicate that these are areas of significant unmet need in the treatment and management of PsA.

Conaghan PG, Alten R, Deodhar A, et al. Relationship of pain and fatigue with health-related quality of life and work in patients with psoriatic arthritis on TNFi: results of a multi-national real-world study [published online July 1, 2020]. RMD Open. doi:10.1136/rmdopen-2020-001240

See original here:
Pain and Fatigue in PsA Linked to Reduced Quality of Life, Physical Function, and Work Productivity - Rheumatology Advisor

DE PERE, Wis. (WFRV) July is Juvenile Arthritis Awareness Month. The disease 300,000 kids have been diagnosed with nationwide.

A De Pere 12-year-old is speaking out about her experience with the autoimmune disease after being diagnosed at just four years old.

Lily Laurent says arthritis mostly impacts her knees and legs. She and her mother, Anne, spoke with WFRV Local 5 about how it has impacted their family and how much of a difference finding a community has made.

When we were first diagnosed, we didnt know another family I mean, I didnt even know kids could get arthritis and we ended up at the rheumatologist, Anne tells WFRV Local 5. It can be scary, and you can feel alone. And there are groups, in Green Bay and the Fox Valley and in Wisconsin, where weve met other families and shes met other kids.

There is no known cure for the disease, but Lily is doing well and heading toward remission.

Her doctor says that patients should watch for the symptoms of juvenile arthritis, such as unusual amounts of aches and pains.

If your child has redness and swelling and especially a lot of stiffness in the morning where theyre walking like an old man or old woman, limping, I mean these are the signs that should, you know, at least, first start with your pediatrician, Dr. Paul Tuttle, a rheumatologist with Orthopedic & Sports Medicine in Green Bay, tells WFRV Local 5.

Lily created a video about her journey with arthritis.

Continued here:
De Pere girl discusses experience with juvenile arthritis - WeAreGreenBay.com

A new intelligence report Rheumatoid Arthritis Treatment Market has been recently Added into Global Market Research collection of top-line market research reports. Global Rheumatoid Arthritis Treatment Market report is a meticulous comprehensive analysis of this market that provides access to direct first-hand insights on the growth trail of market in near term and long term. On the basis of factual advice sourced from authentic industry pros and extensive main industry research, the report provides insights about the historical growth pattern of Rheumatoid Arthritis Treatment Market and current market situation. It then provides short- and long-term market development projections.

Projections are purely based on the detailed analysis of key Market dynamics that are expected to influence Rheumatoid Arthritis Treatment Market performance and their intensity of impacting market growth within the span of assessment period.

Request Sample Report @ https://www.futuremarketinsights.co/reports/sample/REP-GB-3119

In addition to evaluation of dynamics, the report provides In-depth examination of key business trends that are expected to act more prominently in global Rheumatoid Arthritis Treatment Market. The study also provides valued information about the present and upcoming growth opportunities in Rheumatoid Arthritis Treatment Market the important players and new market entrants can capitalize on.

Competitive companies And manufacturers in global market

key players and products offered

Potential and niche segments, geographical regions exhibiting promising growth

A neutral perspective on market performance

Must-have information for market players to sustain and enhance their market footprint

NOTE All statements of fact, opinion, or analysis expressed in reports are those of the respective analysts. They do not necessarily reflect formal positions or views of Future Market Insights.

Request Methodology On This Report @ https://www.futuremarketinsights.co/askus/REP-GB-3119

Opportunity assessment Provided in the Rheumatoid Arthritis Treatment Market report Is important concerning understanding the profitable regions of investment, which are the technical insights for major market players, suppliers, vendors, and other stakeholders in Rheumatoid Arthritis Treatment Market.

In-depth global Rheumatoid Arthritis Treatment Market taxonomy presented in this Report offers detailed insights about each of the market sections and their sub-segments, which are categorized based on par various parameters. An exhaustive regional evaluation of global Rheumatoid Arthritis Treatment Market divides international market landscape into essential geographies.

Regional outlook and country-wise evaluation of Rheumatoid Arthritis Treatment Market Allows for the evaluation of multi-faceted performance of market in all the crucial markets. This advice plans to provide a wider scope of report to readers and identify the most relevant profitable areas in global market place.

Key Regions and Countries Covered in Global Rheumatoid Arthritis Treatment Market Report-

Taxonomy and geographical analysis of the international Rheumatoid Arthritis Treatment Market empowers readers to spot profits in present chances and catch upcoming growth opportunities even until they approach the market location. The analysis given in report is only intended to unroll the economic, societal, regulatory and political scenarios of the marketplace specific to each area and country, which might help prospective market entrants in Rheumatoid Arthritis Treatment Market landscape to comprehend the nitty-gritty of target market regions and invent their strategies accordingly.

We offer tailor-made solutions to fit your requirements, request[emailprotected] https://www.futuremarketinsights.co/customization-available/REP-GB-3119

Major TOC Covered In this Report are:

Here is the original post:
Advancements in Technology to Aid the Growth of the Rheumatoid Arthritis Treatment Market Over the Forecast Period 2017-2027 - Jewish Life News

Here are the top stories recently covered by DocWire News in the rheumatology section. In this edition, read about sarilumab in COVID-19, glucocorticoidsin rheumatoid arthritis (RA), body weight and the risk of tumor necrosis factor inhibitor discontinuation in RA, and healthcare utilization predictors of inflammatory arthritis.

Rheumatoid arthritis (RA) drugsarilumab was not an effective treatment for severely ill COVID-19 patients, according to the results of a phase 3 trial. The U.S.-based study was a phase 3 trial comparing 400 mg sarilumab plus best supportive care versus best supportive care alone for COVID-19 patients requiring mechanical ventilation.According to Regeneron, 80% of Kevzara patients and 77% of best supportive care patients in the primary analysis group sustained adverse events (AEs). Serious AEs documented in at least 3% of patients and were more common in the sarilumab group than the best supportive care group included multiorgan dysfunction syndrome (6% vs. 5%) and hypotension (4% vs. 3%). This study has been stopped in the 400 mg group as well as in a higher-dose cohort.

Astudy compared the effect of low-dose glucocorticoids plus methotrexate and hydroxychloroquine versus placebo plus methotrexate andhydroxychloroquineon symptoms, signs, and inflammation in early RA. After one month of treatment, American College of Rheumatology 20 (ACR20) response was achieved by 55% of the glucocorticoids group and 20% of the placebo group. At month three, 85.0% of the glucocorticoids group and 47.5% of the placebo group achieved ACR20 response; at months six and 12, the rates were 87.5% versus 60.0%, respectively, and 90.0% versus 72.5%, respectively (P<0.05 for all). During the first half of the treatment period, the trial group had significantly lower disease activity score (DAS) 28- erythrocyte sedimentation rate (ESR) scores than the control group. Inflammation, quality of life, and radiological symptoms improved significantly in the glucocorticoids group. Bone erosion did not change in the trial group and worsened in the control group. The correlation coefficient between disease duration and DAS28-ESR score was 0.496 for month one, 0.464 for month three, 0.509 for month six, and 0.550 for month 12. Rates of adverse events did not largely differ between the groups.

RA patients with either a low orhigh body mass index(BMI) are more likely than normal weight RA patients to discontinue treatment withtumor necrosis factor inhibitors (TNFis), according to a study. Final analysis included 5,230 RA patients. TNFi survival, when compared to that of normal weight patients, was significantly shorter among patients inobesity class II(hazard ratio [HR]=1.28; 95% confidence interval [CI], 1.06 to 1.54), obesity class III (HR=1.67; 95% CI, 1.29 to 2.18), and the underweight group (HR=1.30; 95% CI, 1.07 to 1.58). Among the underweight group, the most significant effect was observed for patients on infliximab (HR=1.82; 95% CI, 1.20 to 2.76). In overweight patients, the most significant effect was noticed for patients taking infliximab (obesity class II: HR=1.49; 95% CI, 0.98 to 2.26; obesity class III: HR=1.46; 95% CI, 0.79 to 2.71) and etanercept (obesity class II: HR=1.27; 95% CI, 0.98 to 1.65; obesity class III: HR=1.79; 95% CI, 1.25 to 2.55).

Patients who eventually go on to be diagnosed withinflammatory arthritis (IA)often present withmusculoskeletal symptoms, infections, and comorbidity leading up to their diagnosis, according to a study. During the 1.5-year period before their diagnosis, IA patients were significantly more likely than controls to have health visits for musculoskeletal symptomsprimarily for shoulders, wrists, fingers, and kneesand carpal tunnel syndrome. The odds ratio (OR) was highest at six months prediagnosis (3.2; 95% confidence interval [CI], 2.8 to 3.5), followed by 12 months (OR=2.8; 95% CI, 2.5 to 3.1) and 18 months (OR=2.5; 95% CI, 2.2 to 2.8).

See the original post:
Rheum Round-up: Sarilumab Flops in COVID-19, RA TNFi Termination and Body Weight, and more - DocWire News

A drug used to treat brain haemorrhage and arthritis could help patients battling COVID-19.

A coronavirus patient at Wythenshawe Hospital has become the first to take part in the trial a drug called Anakinra.

Anakinra is an immunosuppressive drug mainly used to treat rheumatoid arthritis but also certain types of brain haemorrhage.

Researchers say the drug can combat severe infections and multiple organ failure triggered by an overreactive response by the bodys immune system.

This immune response can result in death and can occur in critically-ill COVID-19 patients.

The new trial is comparing the drugs effectiveness in treating critically ill patients when administered either by injection under the skin or into the vein.

Dr Tim Felton, a consultant in Intensive Care and Respiratory Medicine at Manchester University NHS Foundation Trust (MFT), is leading the study.

He said: "Anakinra is highly effective in treating overreactive immune response and severe infections.

"Because of this it could prove effective in treating COVID-19 patients, and several global trials are now underway to investigate this.

"The drug is typically administered as an injection either into the vein or under the skin.

"We think injection under the skin is a more efficient way of delivering the drug and thats why with SCIL-1Ra we want to compare the two methods.

"We hope to show one method is more effective than the other and deliver better outcomes for patients."

Dr Bannard-Smith, an ICU consultant and lead Covid researcher at the MRI, added: Were incredibly grateful to our patient and their family for participating in the trial, and our fantastic team at Wythenshawe Hospital for their excellent patient care and hard work in coordinating this study.

"MFT is at the forefront in delivering cutting-edge research to fight COVID-19. Anakinra is currently being trialled as a potential COVID-19 treatment by several major UK and international studies, and we hope this one will make a vital contribution to wider efforts to understand the drugs effectiveness."

The study, called SCIL-1Ra, aims to recruit 40 adult patients in intensive care with confirmed or clinically suspected COVID-19.

It's one of many COVID-19 treatment trials underway at hospitals across Greater Manchester.

View original post here:
Drug used to treat brain haemorrhage and arthritis is being tested on Covid patients at Wythenshawe Hospital - Manchester Evening News

The research report on theglobal Rheumatoid Arthritis Treatment Market is a comprehensive guide for new market entrants. The report provides the market history of each product retailed by the company. It likewise gives a background marked by item types, innovation and volume during the figure time frame. The growth rate, challenges and obstacles are also explained in the Global Rheumatoid Arthritis Treatment study report. The report features the pace of improvement of the methodologies, items and advances utilized in the creation, assembling and promoting of the item.

The following Top manufacturers are evaluated in this report: Pfizer, Inc., Johnson & Johnson, Abbvie, Inc., F. Hoffmann-La Roche AG, Merck & Co., Inc., and Amgen, Inc.,

* The sample copy includes: Report Summary, Table of Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.

To Get More Insightful information | Request a sample copy @ https://www.coherentmarketinsights.com/insight/request-sample/166

This report sample includes

Brief Introduction to the research report.Table of Contents (Scope covered as a part of the study)Top players in the marketResearch framework (presentation)Research methodology adopted by Coherent Market Insights

The market report contains the following chapters:

Chapter 1: The Global Market Research Report Rheumatoid Arthritis Treatment Help Understand Crucial Information About The Given Market. Chapter 2: The report provides a detailed study on each actor having a major impact on the global market Rheumatoid Arthritis Treatment, such as company profiles, the latest technological advances of market players and the product profile of the player currently available in the market, as well as the regions in which they operate mainly. Chapter 3: It helps to understand the key product segments and their future on the global market Rheumatoid Arthritis Treatment. It provides strategic solutions and recommendations in key business sectors based on market estimates. Chapter 4: The report also presents an eight-year forecast survey based on expected market growth.

The Global Rheumatoid Arthritis Treatment Market report analyzes the production of goods, supply, sales and the current state of the market in detail. In addition, the report examines the market share of production and sales of products, as well as capacity, production capacity, sales trends, cost analysis and revenue generation. Several other factors such as import/export status, industrial statistics, supply and demand ratio, gross margin and the structure of the industrial chain were also studied in the Global Rheumatoid Arthritis Treatment Reports.

Rheumatoid Arthritis Treatment Market Regional Analysis:

Geographically, the Rheumatoid Arthritis Treatment market is segmented across the following regions: North America, Europe, Latin America, Asia Pacific, and Middle East & Africa.

Key Coverage of Report:

Key insights of the report:

The report conveys key measurements on the current market status of the Rheumatoid Arthritis Treatment makers and is a dependable wellspring of direction and course for the organizations and people intrigued by the business in the industry. The report delivers an overview of the industry, including the basic definition, applications, the latest manufacturing technology, and others. The report comprises of the company profile, product specifications, production capacity, production value, and market shares for the key competitors. The market is additionally partitioned by an organization, by nation, and by application/type for the serious scene investigation. The report forecasts market development trends of the Rheumatoid Arthritis Treatment industry from 2016 to 2027.Analysis of the upstream raw materials, downstream demand and current market dynamics is also carried out efficiently. The report states the important growth prospects and proposals for a new project in the global Rheumatoid Arthritis Treatment Industry.

Note: *The Download PDF brochure only consists of Table of Content, Research Framework, and Research Methodology.

To Get PDF Brochure Click Here @ https://www.coherentmarketinsights.com/insight/request-pdf/166

STAY HOME STAY SAFE

Read this article:
Rheumatoid Arthritis Treatment Market trends, drivers, restraints, and opportunities 2020-2026 - Daily Research Chronicles

The stereotypic image of a person with gout is the overweight middle-aged male who indulges in rich food and consumes too much alcohol. Although this may certainly be an example of someone with gout, this common and complex form of arthritis can affect anyone.

Gout is, in fact, an inherited metabolic disease related to insulin resistance. Gout typically manifests as acute, very painful arthritis of the big toe but in reality, can affect any of the major joints in the body. Although the last thing you want to experience is painful arthritis, gout has other associations and as with all other medical conditions, the best treatment of gout is prevention.

The basic metabolic abnormality is an elevated uric acid a waste product created during the normal breakdown of purines (a type of chemical found in foods and drinks). The crystals of uric acid precipitate in the joint leading to the painful arthritis. But these crystals of uric acid can also affect the kidney leading to varying degrees of kidney impairment and hypertension (high blood pressure).

There are very effective treatments to settle down an acute episode, but there is also a drug that has been available for many years, which in most cases is very safe: allopurinol (sold under the brand names Allohexal, Allosig, Progout and Zyloprim). Taking allopurinol once the episode has settled in increasing doses to a maintenance of 300mg daily should prevent gout with minimal, if any, side effects. This will not only prevent further episodes of gout but will also protect the kidney from damage and help reduce blood pressure.

Interestingly, a recent large study published in the Journal of Hypertension of just under 24,000 people with hypertension showed the commonly prescribed blood pressure pill amlodipine when compared with diuretic or another commonly prescribed group of blood pressure drugs, ACE inhibitors, lowers the risk for gout by around 35 per cent.

So if you have unfortunately experienced gout in your life and also have hypertension, its worth discussing with your doctor the preventative management for gout, but also taking the appropriate therapy for your blood pressure.

IMPORTANT LEGAL INFO This article is of a general nature and FYI only, because it doesnt take into account your personal health requirements or existing medical conditions. That means its not personalised health advice and shouldnt be relied upon as if it is. Before making a health-related decision, you should work out if the info is appropriate for your situation and get professional medical advice.

Follow this link:
The best way to treat a gout attack - Starts at 60

TheGlobal Psoriatic Arthritis Therapeutics Market Outlook and Forecast 2020-2025A fundamental outline of thePsoriatic Arthritis Therapeutics Marketniche is presented by the Psoriatic Arthritis Therapeutics Market report that entails definitions, classifications, applications together with industry chain framework. ThePsoriatic Arthritis Therapeutics Marketreport provides a far-reaching evaluation of necessary market dynamics and the latest trends. It also highlights the regional market, the prominent market players, as well as several market segments [Product, Applications, End-Users, and Major Regions], and sub-segments with a wide-ranging consideration of numerous divisions with their applications.

Our Free Complimentary Sample Report Accommodate a Brief Introduction of the research report, TOC, List of Tables and Figures, Competitive Landscape and Geographic Segmentation, Innovation and Future Developments Based on Research Methodology

Request Free Sample Report of Psoriatic Arthritis Therapeutics Market Report @https://www.zionmarketresearch.com/sample/psoriatic-arthritis-therapeutics-market

Some of the Major Market Players Are:

AbbVie, Amgen, Celgene Corporation, Janssen Biotech, UCB, Pfizer, Biogen, Novartis AG, Eli Lilly and Company

Further, the report acknowledges that in these growing and promptly enhancing market circumstances, the most recent advertising and marketing details are very important to determine the performance in the forecast period and make essential choices for profitability and growth of the Psoriatic Arthritis Therapeutics Market. In addition, the report encompasses an array of factors that impact the growth of the Psoriatic Arthritis Therapeutics Market in the forecast period. Further, this specific analysis also determines the impact on the individual segments of the market.

Furthermore, the study assessed major market elements, covering the cost, capacity utilization rate, growth rate, capacity, production, gross, usage, revenue, export, supply, price, market share, gross margin, import, and demand. In addition, the study offers a thorough segmentation of the global Psoriatic Arthritis Therapeutics Market on the basis of geography [ Latin America, North America, Asia Pacific, Middle & East Africa, and Europe] , technology, end-users, applications, and region.

Download Free PDF Report Brochure@https://www.zionmarketresearch.com/requestbrochure/psoriatic-arthritis-therapeutics-market

Note In order to provide more accurate market forecast, all our reports will be updated before delivery by considering the impact of COVID-19.

(*If you have any special requirements, please let us know and we will offer you the report as you want.)

The Psoriatic Arthritis Therapeutics Market report is a collection of pragmatic information, quantitative and qualitative estimation by industry experts, the contribution from industry connoisseurs and industry accomplices across the value chain. Furthermore, the report also provides the qualitative results of diverse market factors on its geographies and segments.

The Psoriatic Arthritis Therapeutics Market report is an appropriate compilation of all necessary data for the residential, industrial. & commercials buyers, manufacturers, governments, and other stakeholders to implement their market-centric tactics in line with the projected as well as the prevailing trends in the Psoriatic Arthritis Therapeutics Market. Apart from this, the report also provides insightful particulars of the existing policies, laws, together with guidelines.

Inquire more about this report @https://www.zionmarketresearch.com/inquiry/psoriatic-arthritis-therapeutics-market

Promising Regions & Countries Mentioned In The Psoriatic Arthritis Therapeutics Market Report:

Chapters Covered in Research Report are :

Chapter 1,2 :The goal of global Psoriatic Arthritis Therapeutics Market covering the market introduction, product image, market summary and development scope.

Chapter 3, 4 :Global Market Competitions by Manufacturers, Sales Volume and Market Profit.

Chapter 5,6,7:Global Supply (Production), Consumption, Export, Import by Regions like United States, Asia-Pacific, China, India, Japan. Conducts the region-wise study of the market based on the sales ratio in each region, and market share from 2015 to 2024

Chapter 8,9,10:Global Market Analysis by Application, Cost Analysis, Marketing Strategy Analysis, Distributors/Traders

Chapter 11,12 :Market information and study conclusions, appendix and data sources.

The market report also identifies further useful and usable information about the industry mainly includes Psoriatic Arthritis Therapeutics Market development trend analysis, investment return and feasibility analysis. Further, SWOT analysis is deployed in the report to analyze the key global market players growth in the Psoriatic Arthritis Therapeutics Market industry

Request the coronavirus impact analysis across industries and market

Request impact analysis on this market @https://www.zionmarketresearch.com/custom/4271?covid19=true

Purposes Behind Buying Psoriatic Arthritis Therapeutics Market Report:-

Also, Research Report Examines:

Thanks for reading this article; you can also get individual chapter wise section or region wise report version like North America, Europe or Asia.

Continue reading here:
Global Psoriatic Arthritis Therapeutics Market Outlook and Forecast 2020-2025 - 3rd Watch News

Arthritis is the most common form of peripheral joint arthritis and cause of disability in the UK. It affects mostly the knee, hip, hand, and feet joints. It is a chronic musculoskeletal disorder characterised by involvement of all joint structures including the synovial membrane, cartilage and bone. Those suffering with the condition experience joint pain, reduced participation in daily activities and poor quality of life. Fortunately, including more of these delicious fruits could help.

Tart cherries get their rich red colour and many of their powerful anti-inflammatory and antioxidant benefits from the flavonoid anthocyanin, said the Arthritis Foundation.

The health site added: These properties make tart cherries a popular research subject, and some investigators compare the effects to nonsteroidal anti-inflammatory drugs.

One study found that drinking tart cherry juice two times per day for three weeks resulted in considerable reductions in vital inflammation markers, especially for participants who had the highest inflammation levels at the start of the study.

READ MORE:Arthritis pain - breakfast swap that could lower your risk of symptoms

Watermelons are high in the carotenoid beta-cryptoxanthin, which helps to reduce the risk of rheumatoid arthritis, according to studies which followed peoples dietary habits over time, said Arthritis Foundation.

Nutritionist Victoria Jarzabkowski added: The lycopene in watermelon makes it an anti-inflammatory fruit.

Lycopene is also known to help protect certain cancers and lower heart attack risk.

DON'T MISSArthritis: A vegetable to ease pain[DIET]Arthritis treatment: Take this herbal extract to reduce pain[REMEDY]Arthritis pain - the best oil to use while cooking your dinner[DIET]

Unlike most fruits, avocados are a good source of vitamin E, a micronutrient with anti-inflammatory effects said Arthritis Foundation.

The site added: Diets high in these compounds are linked to decreased risk of the joint damage seen in early osteoarthritis.

Studies also show eating avocados daily increases good HDL cholesterol and lowers bad LDL cholesterol.

When it comes to foods to avoid, processed foods are up there.

Foods including baked goods, pre-packaged meals and snacks.

These items contain trans-fat to help preserve them, and trans fats trigger systemic inflammation.

Its imperative to carefully read food labels as many contain hydrogenated oils which should be avoided.

There is no cure for arthritis, but there are many treatments that can help slow it down, said the NHS.

It added: Osteoarthritis treatments include lifestyle changes, medicines and surgery.

Treatment for rheumatoid arthritis aims to slow the conditions progress and minimise joint inflammation. This helps prevent joint damage.

Treatments include medication, physiotherapy and surgery.

See more here:
Arthritis: Three of the best fruits to incorporate into your diet to reduce symptoms - Express

Magnetic resonance imaging (MRI)-detected erosions of the hand and feet were not predictive of rheumatoid arthritis (RA) in patients with arthralgia, according to study data published in the Scandinavian Journal of Rheumatology. Instead, MRI-detected subclinical inflammation was the strongest correlate of later disease progression in patients with clinically suspect arthralgia.

The study cohort comprised patients with recent-onset (<1 year) arthralgia in the small joints who received care at a rheumatology clinic in Leiden, the Netherlands. Patients were enrolled between April 2012 and October 2018. Individuals were excluded if clinical arthritis was detected at baseline or if another etiology for joint arthralgia was present. At baseline, patients underwent a physical examination, blood draw, and high-contrast MRI of the hands and feet. Erosions were scored using the Rheumatoid Arthritis Magnetic Resonance Imaging Scoring system. Follow-up visits were conducted at 4, 12, and 24 months. Patients who initiated treatment with disease-modifying antirheumatic drugs during follow-up were excluded from analyses.

The primary outcome was diagnosis of inflammatory arthritis, determined by the treating rheumatologist. Multivariable logistic regression was performed to assess the relationship between MRI-detected lesions and later diagnosis of arthritis. Analyses were stratified by anticitrullinated protein/peptide antibody (ACPA) positivity and adjusted for patient age and subclinical inflammation levels.

The study cohort comprised 490 patients, of whom 83 developed inflammatory arthritis during follow-up. Median follow-up time to inflammatory disease diagnosis was 14 weeks (interquartile range, 3-23 weeks). Median follow-up duration in patients who did not progress to arthritis was 103 weeks (interquartile range, 51-113 weeks). Median total erosion score was greater in patients who progressed to arthritis compared with patients who did not.

The presence of MRI-detected erosions was not significantly associated with arthritis development in either the univariate model (hazard ratio, 1.40; 95% CI, 0.86-2.28) or the model adjusted for age and subclinical inflammation (hazard ratio, 0.97; 95% CI, 0.59-1.59). Analyses were then restricted to RA-specific erosions: grade 2 erosions, erosions of the fifth metatarsophalangeal joints (MTP5), and erosions in MTP1 in patients aged <40 years. None of these erosion types were predictive of later progression to inflammatory disease.

In analyses stratified by ACPA status, these trends persisted: MRI-detected erosions did not predict disease progression in either ACPA subset. The researchers instead found subclinical inflammation level to be the strongest predictor of later disease progression. Area under the receiver operating characteristic curve (AUC) was 0.73 for subclinical inflammation vs 0.54 for MRI erosion. When MRI-detected erosion was added to the model, the AUC remained at 0.73, suggesting that prognostic accuracy was not improved by erosion assessment.

Results from this longitudinal study indicated that MRI-detected erosions of the hands and feet are not predictive of later arthritis development in patients with clinically suspect arthralgia. This implies that evaluating MRI erosions of [patients with clinically suspect arthralgia] is superfluous if MRI-detected subclinical inflammation is assessed, the investigators wrote.

Reference

Wouters F, Matthijssen XME, Boeters DM, et al. Do magnetic resonance imaging-detected erosions predict progression to rheumatoid arthritis in patients presenting with clinically suspect arthralgia? A longitudinal study [published online June 2, 2020]. Scand J Rheumatol. doi:10.1080/03009742.2020.1737221

View post:
MRI-Detected Erosions of the Small Joints Not Predictive of Later Rheumatoid Arthritis - Rheumatology Advisor

Arthritis affects around 10 million people in the UK, according to the charity Versus Arthritis. Don't wait until symptoms become unbearable, notice these common signs to begin early treatment.

Charity Arthritis Foundation point out the four most common warning signs of the condition.

1. Pain

First, there will be a sensation of pain. This can come and go whether resting or moving or it may be persistent.

The pain can be found in one specific area of the body or it could occur in different parts.

2. Swelling

There are various types of arthritis (which will be noted later), but a certain type of arthritis can cause swelling.

The skin over the affected joint can become red and swollen, feeling warm to the touch.

Swelling can last for a couple of days, which requires medical attention. This is also true if swelling occurs more than three times in a month.

3. Stiffness

Stiffness tends to be apparent when waking up first thing in the morning especially if it lasts longer than an hour after rising.

READ MORE:Vitamin deficiency warning: New study suggest vitamin deficiencies impair brain function'

It also reveals itself after sitting at a desk for a long time, or you may feel stiff after taking a long car journey.

4. Difficulty moving a joint

If you're finding it difficult or painful to get up from a chair, it's likely you have arthritis.

Types of arthritis

There are lots of different types of arthritis far too many to delve into in one article.

The three most common types of arthritis are: osteoarthritis, gout and rheumatoid arthritis.

DON'T MISS

Osteoarthritis

Versus Arthritis explained that osteoarthritis begins with the roughening of cartilage.

Cartilage is responsible for cushioning the ends of bones, however, once it begins to roughen, tiny bits of extra bones (osteophytes) can extend from bones in the joint.

Moreover, there can be an increase in the amount of thick fluid inside the joint.

And the joint capsule can stretch, resulting in the joint losing its shape.

Gout

Gout is a type of inflammatory arthritis that can cause painful swelling in the joints (spoken about earlier).

The most common joint affected is the big toe, but any joint suffering from gout can become red and hot.

The skin over the inflamed joint can look shiny and can peel. The condition is caused by too much urate (uric acid) in the body.

Although a small amount of urate is normal, excess urate can develop based on genetics, or what you eat or drink.

Rheumatoid arthritis

Rheumatoid arthritis is another type of inflammatory arthritis, when the body's immune system mistakenly attacks the body's joints.

The autoimmune disorder collects extra blood and fluid to the affected joint(s) which can cause a number of problems.

For example, it can make moving the joints difficult and painful, as the fluid can irritate nerve endings.

Moreover, the extra fluid can stretch the joint capsule, dislodging the joint from its original position.

Read the rest here:
Arthritis symptoms: The four most common signs you have the health condition - Express

Eating dark, leafy vegetables along with fish and fruits similar to the Mediterranean diet is one of the best ways to eat to help reduce symptoms of arthritis.

Dr Lex Mauger, co-author of the study and Director for BSc Sports Science at the University of Kent, said: The Mediterranean diet has previously been associated with a number of health benefits, but the exciting finding with this study is that specific guidance on adhering to this type of diet can change eating behaviour and result in a number of beneficial physiological changes, relevant to osteoarthritis, in a relatively short period of time.

As osteoarthritis is a chronic disease, treatment is primarily about managing the symptoms, and this study shows that eating healthily may help form part of that treatment strategy.

Benefits from the intervention in this study were evident after only four months, so it is possible that an even greater benefit could be seen in people who make longer-term improvements to their normal diet.

Read the original:
Arthritis: Eating more of this vegetable will help reduce pain felt in the joints - Express

Serum iron and serum hepcidin levels are directly and indirectly associated with osteoporosis in patients with rheumatoid arthritis (RA), according to study results published in Scientific Reports.1

Previous research has reported lower serum hepcidin and higher serum iron levels in patients with osteoporosis.2 In this study, investigators aimed to determine the correlation between serum hepcidin levels and degree of osteoporosis in patients with RA.

A total of 262 patients with RA were included in the study (77.5% women; mean age, 67.511.4 years), a majority of whom had low disease activity (82.4%) or were in remission (77.1%), according to disease activity score in 28 joints based on C-reactive protein (DAS28-CRP) and Clinical Disease Activity Index. Data on disease characteristics indicated a mean disease duration of 13.610.6 years, with mean disease activity scores of DAS28-CRP and erythrocyte sedimentation rate of 2.21.5 and 2.61.0, respectively. Measurements of mean serum hepcidin (14.319.7 ng/mL), fibroblast growth factor (FGF23; 59.332.9 pg/mL), and 25(OH)D levels (16.56.9 ng/mL) were also collected. Study participants were categorized into 4 groups based on these levels and associations with disease parameters were analyzed.

Higher hepcidin levels were related to increased inflammation, higher ferritin and iron levels, lower unsaturated iron binding capacity, and higher 25(OH)D levels. In addition, RA inflammation and 25(OH)D levels were significantly related to serum hepcidin levels. Higher serum 25(OH)D levels were associated with older age, lower estimated glomerular filtration rate (eGFR), higher ferritin and hepcidin levels, and higher Z score of femoral activity. Higher serum FGF23 levels were associated with older age, lower eGFR, higher body mass index, and 25(OH)D levels.

Overall, results indicated that serum iron levels were positively correlated to bone mineral density (BMD), and serum hepcidin and ferritin levels were positively related to 25(OH)D levels, which were positively associated with the femoral Z score. Serum hepcidin levels and iron metabolism were shown to both directly and indirectly affect osteoporosis in patients with RA.

Study limitations included the use of data from a single center and the absence of control participants. In addition, lifestyle factors such as diet, smoking, and alcohol intake were not analyzed.

References

1. Sato H, Takai C, Kazama JJ, et al. Serum hepcidin level, iron metabolism and osteoporosis in patients with rheumatoid arthritis [published online June 18, 2020]. Sci Rep. doi:10.1038/s41598-020-66945-3

2. Liu B, Liu C, Zhong W, Song M, Du S, Su J. Reduced hepcidin level features osteoporosis. Exp Ther Med. 2018;16:1963-1967.

More:
Serum Iron and Hepcidin Levels Associated With Osteoporosis in Patients With Rheumatoid Arthritis - Rheumatology Advisor

Suffering from arthritis? Youre not the only one since studies show that it affects over 10 million people in the U.K. Thankfully, you can help reduce your symptoms by adding certain fruits to your everyday diet.

Top Fruits That Could Help Ease Arthritis Symptoms

Affecting mostly the knee, hip, hands and feet joints, arthritis is a common condition all across the world and affects several age groups. In fact, statistics show that the chronic musculoskeletal disorder is the most common cause of disabilities in the U.S. Characterized by the involvement of all joint structures in our body, it usually gives joint pain, reduced participation in daily activities and a generally poorer quality of life for those who are suffering from it.

Fortunately, changing your diet and making healthier food choices can do a lot to help alleviate these symptoms. One such way is by eating nutrient-rich fruits. Here are some of the best ones that can help your condition:

Tart Cherries

Per the Arthritis Foundation, tart cherries get their red and vibrant color from the antioxidant anthocyanin, which has anti-inflammatory benefits that can help your joints. Theyre also incredibly tasty and can be enjoyed as a healthy snack to munch on instead of the usual processed sweets. "One study found that drinking tart cherry juice two times per day for three weeks resulted in considerable reductions in vital inflammation markers, especially for participants who had the highest inflammation levels at the start of the study," wrote the foundation.

Avocado

Essentially considered as a superfruit, avocados are easily available, cheap and host tons of health benefits. As for people suffering from arthritis, however, theyd be glad to know that avocados are filled with vitamin E, which is a macronutrient with anti-inflammatory capabilities that can help decrease the risk of joint damage thats usually seen in early stages of osteoarthritis.

Watermelon

Mostly made up of water, watermelons are not only refreshing but are also filled with the carotenoid beta-cryptoxanthin, which helps reduce the risk of rheumatoid arthritis. Additionally, the lycopene in watermelon also has anti-inflammatory effects and can contribute to heart health.

Pixabay

Video: The Potential Side Effects of Plan B (Shape)

UP NEXT

Read this article:
Fruits To Eat To Reduce Arthritis Symptoms - MSN Money

Background:The concomitant presence of two autoimmune diseases systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) in the same patient is known as rhupus. We evaluated a group of patients with rhupus to clarify further their clinical, serological and immunogenic features in a multi-centre cohort. In addition, the study aimed to explore the utility of the 2019 European League Against Rheumatism/American College of Rheumatology (EULAR/ACR) SLE classification criteria in our group of patients with rhupus.

Methods:This was a cross-sectional study. We included rhupus patients from 11 different rheumatology departments, and compared them to SLE and RA patients at a ratio of 2:1. All information was recorded following a pre-established protocol.

Results:A total of 200 patients were included: 40 rhupus patients and 80 each of SLE and RA patients as controls. Disease duration was similar among SLE and rhupus groups (around 13 years), but the RA group had a significantly lower disease duration. Main clinical manifestations were articular (94.2%), cutaneous (77.5%) and haematological (72.5%). Rhupus patients had articular manifestations similar to those expected in RA. Only 10% of rhupus patients had renal involvement compared with 25% of those with SLE (p< 0.05), while interstitial lung disease was more common in patients affected by RA. The 2019 EULAR/ACR SLE criteria were met in 92.5% of the rhupus patients and in 96.3% of the SLE cohort (p> 0.05). Excluding the joint domain, there were no differences between the numbers of patients who met the classification criteria.

Conclusion:Rhupus patients follow a particular clinical course, with full expression of both SLE and RA in terms of organ involvement, except for a lower prevalence of kidney affection. The new 2019 EULAR/ACR SLE criteria are not useful for differentiating SLE and rhupus patients. A new way of classifying autoimmune diseases is needed to identify overlapping clusters.

Keywords:Arthritis; poly-autoimmunity; rheumatoid arthritis; rhupus; systemic lupus erythematosus.

Read more:
A Comparative Study on Clinical and Serological Characteristics Between Patients With Rhupus and Those With Systemic Lupus Erythematosus and...

New York, July 9, 2020: Market Research Engine has published a new report titled asSmall Molecule Therapies for Rheumatoid Arthritis MarketSize, By Product (Disease Modifying Anti-Rheumatic Drugs, Non-Steroidal Anti-Inflammatory Drugs, Corticosteroids), By Region, Market Analysis Report, Forecast 2018-2024.

FYI, you will get latest updated report as per the COVID-19 Impact on this industry. Our updated reports will now feature detailed analysis that will help you make critical decisions.

Increasing ageing population and healthcare expenditure will expand the small molecule therapies for rheumatoid arthritis market size over the forecast time line. Rising investments in drug development program and drug discovery will further support in stimulating industry size. Stringent regulations related to efficacy in clinical development may affect the industry revenue generation till 2024.

Browse Full Report: https://www.marketresearchengine.com/small-molecule-therapies-for-rheumatoid-arthritis-market

Regulatory approvals for leflunomide and etanercept has led to various developments in the disease modifying anti-rheumatic drugs (DMARDs) which are used for the treatment of rheumatoid arthritis. Of which leflunomide is a small molecule and non-biological DMARD, whose usage will support in promoting industry growth rate during the study period.

The small molecule therapies for rheumatoid arthritis market is segmented on the lines of its product and regional. The basis of product the market is segmented into Disease Modifying Anti-Rheumatic Drugs, Non-Steroidal Anti-Inflammatory Drugs, and Corticosteroids. The small molecule therapies for rheumatoid arthritis market on geographic segmentation covers various regions such as North America, Europe, Asia Pacific, and Rest of World. Each geographic market is further segmented to provide market revenue for selected countries such as the U.S., Canada, Germany, UK, France, Italy, China, India, Japan, Brazil, South Africa and others.

Competitive Rivalry

AbbVie, Amgen, Johnson & Johnson, Novartis, Pfizer, and UCB Pharma are among the major players in the global small molecule therapies for rheumatoid arthritis market share. The companies are involved in several growth and expansion strategies to gain a competitive advantage. Industry participants also follow value chain integration with business operations in multiple stages of the value chain.

The Small Molecule Therapies for Rheumatoid Arthritis Market has been segmented as below:

The Small Molecule Therapies for Rheumatoid Arthritis Market is segmented on the lines of Small Molecule Therapies for Rheumatoid Arthritis Market, By Product and Small Molecule Therapies for Rheumatoid Arthritis Market, By Region.

Small Molecule Therapies for Rheumatoid Arthritis Market, By Product this market is segmented on the basis of Disease Modifying Anti-Rheumatic Drugs, Non-Steroidal Anti-Inflammatory Drugs and Corticosteroids. Small Molecule Therapies for Rheumatoid Arthritis Market, By Region this market is segmented on the basis of North America, Europe, Asia Pacific and Rest of World.

The report covers:

Report scope:

The scope of the report includes a detailed study of small molecule therapies for rheumatoid arthritis market with the reasons given for variations in the growth of the industry in certain regions.

The report covers a detailed competitive outlook including the market share and company profiles of the key participants operating in the global market. Key players profiled in the report include AbbVie, Amgen, Johnson & Johnson, Novartis, Pfizer, and UCB Pharma. Company profile includes assigning such as company overview, product landscape, financial overview, and recent developments.

The top company reports are intended to provide our buyers with a snapshot of the industrys most influential players.

Reasons to Buy this Report:

Request Sample Report from here: https://www.marketresearchengine.com/small-molecule-therapies-for-rheumatoid-arthritis-market

Table of Contents:

1. Introduction

2. Research Methodology

3. Executive Summary

4. Market Overview 4.1. Introduction 4.2. Drivers 4.2.1. Ageing population 4.2.2. Attrition of new small molecule drugs in RA clinical development 4.3. Restraints 4.3.1. High cost of RA drugs 4.3.2. Approval of the drug by regulatory authorities 4.4. Opportunities 4.4.1. Drug discovery and drug development program 4.4.2. Unmet medical need 4.5. Challenges 4.5.1. Need for rheumatologists 4.5.2. Market dominance by TNF-alpha inhibitors

5. Small Molecule Therapies for Rheumatoid Arthritis Market, By Product

6. Competitive Landscape

7. Company Profile 7.1. AbbVie 7.1.1. Company Overview 7.1.2. Product/Service Landscape 7.1.3. Financial Overview 7.1.4. Recent Developments 7.2. Amgen 7.2.1. Company Overview 7.2.2. Product/Service Landscape 7.2.3. Financial Overview 7.2.4. Recent Developments 7.3. Johnson & Johnson 7.3.1. Company Overview 7.3.2. Product/Service Landscape 7.3.3. Financial Overview 7.3.4. Recent Developments 7.4. Novartis 7.4.1. Company Overview 7.4.2. Product/Service Landscape 7.4.3. Financial Overview 7.4.4. Recent Developments 7.5. Pfizer 7.5.1. Company Overview 7.5.2. Product/Service Landscape 7.5.3. Financial Overview 7.5.4. Recent Developments 7.6. UCB Pharma 7.6.1. Company Overview 7.6.2. Product/Service Landscape 7.6.3. Financial Overview 7.6.4. Recent Developments

Other Related Market Research Reports:

Sexually Transmitted Disease Therapeutics Market Growth, Status and Forecast by 2024

Urinary Incontinence and Overactive Bladder Market Global Industry Analysis, Size, Share, Growth by 2024

About MarketResearchEngine.com

Market Research Engine is a global market research and consulting organization. We provide market intelligence in emerging, niche technologies and markets. Our market analysis powered by rigorous methodology and quality metrics provide information and forecasts across emerging markets, emerging technologies and emerging business models. Our deep focus on industry verticals and country reports help our clients to identify opportunities and develop business strategies.

Media Contact

Company Name: Market Research Engine

Contact Person: John Bay

Email:[emailprotected]

Phone:+1-855-984-1862

Country: United States

Website: https://www.marketresearchengine.com/

Address: 3422 SW 15 Street, Suite #8942, Deerfield Beach, FL 33442, United States

Continued here:
Small Molecule Therapies for Rheumatoid Arthritis Market to Register Impressive Growth Rate as Demand Rambles during Lockdown - Cole of Duty

Although the adverse effects of systemic glucocorticosteroids (GCs) are well known, their association with hypertension in rheumatoid arthritis (RA) has been unclear. Now, a large population-based study shows that the drugs are linked to a 17% overall increased risk for incident hypertension among patients with RA.

Further, when the researchers stratified participants by dose category, they found that doses higher than 7.5 mg were significantly associated with hypertension. Cumulative dosage was not tied to any clear pattern of risk.

The authors, led by Ruth E. Costello, MSc, a researcher at the Center for Epidemiology Versus Arthritis in the Center for Musculoskeletal Research at the University of Manchester, United Kingdom, conclude that patients who are taking these drugs for the treatment of RA should be monitored for high blood pressure, which is an important but modifiable cardiovascular risk factor, and treated appropriately.

The results of Costello and colleagues' study were published June 27 in Rheumatology.

"While fractures associated with these steroid drugs are well studied, hypertension is a side effect that seems to have been less well studied, and yet it is an important cardiovascular risk factor that can be managed," Costello told Medscape Medical News.

To better understand the possible association, Costello and colleagues identified 17,760 patients who were newly diagnosed withRA between 1992 and 2019 and were included in the Clinical Practice Research Datalink, which represents about 7% of the UK population. None of the patients had hypertension at initial RA diagnosis. Slightly more than two thirds were women (68.1%), and the mean age was 56.3 years.

Of those patients, 7421 (41.8%) were prescribed GCs during post-diagnosis follow-up. Most patients (73%) were followed for at least 2 years.

Patients who used GCs were slightly older than never-users (mean age, 57.7 vs 55.3 years), were predominantly women, had a history of smoking, and had more comorbidities.

The overall incidence rate (IR) of hypertension was 64.1 per 1000 person-years (95% CI, 62.5 65.7). There were 6243 cases of incident hypertension over 97,547 person-years of follow-up.

Among those exposed to GCs, 1321 patients developed hypertension, for an IR of 87.6 per 1000 person-years. Among unexposed participants, the IR for hypertension was 59.7 per 1000 person-years. In Cox proportional hazards modeling, GC use was associated with a 17% increased risk for hypertension (hazard ratio, 1.17; 95% CI, 1.10 1.24).

The researchers note that 40% of GC users with hypertension were not prescribed an antihypertensive agent at any point during the study. "Whilst some may have been offered lifestyle advice, left untreated this has important implications in terms of addressing modifiable risk factors in an RA population already at increased risk of CV disease," they write.

They note that cardiovascular disease is a major driver of the elevated mortality risk seen among adults with RA compared with the general population and that recent treatment recommendations address management of cardiovascular risks in these patients.

"There are several routes by which GCs may promote cardiovascular disease, including hypertension, metabolic changes, diabetes, and weight gain. We don't currently know the extent to which each of these individual mechanisms may be increasing cardiovascular disease," said Costello.

"Glucocorticoids increase fluid retention and promote obesity and hypertension," said Rajat S. Bhatt, MD, a rheumatologist at Prime Rheumatology and Memorial Hermann Katy Hospital in Richmond, Texas, who sees hypertension in GC users in his clinical practice. "So patients need to be monitored for these risk factors," he told Medscape Medical News.

Although hypertension may be a significant factor in the increase in cardiovascular disease in the RA population, Bhatt said the major driver is likely the intrinsic inflammatory state caused by the disease itself. As to why the GC-hypertension connection has flown under the radar in RA, he added, "That specific link has been difficult to tease out since RA patients are often on multiple medications."

In regard to the role of dosage, Bhatt said that hypertension risk increases with higher GC doses, as the UK study indicates, and usually subsides when patients stop using GCs.

"Whether the observed dose association is causal or influenced by the underlying disease severity, our results suggest we should be vigilant in patients on all doses of GC, especially higher doses," Costello added.

In regard to using drugs that are less cardiotoxic than CGs, Bhatt said that there are clinical scenarios in which GC therapy is the best choice, so just switching to nonsteroidal drugs is no panacea. "All RA drugs have adverse side effects, and anyway, the goal of rheumatology treatment is always to get patients off corticosteroids as soon as possible," he said.

Costello and colleagues note that their results are consonant with earlier research, including a single-center cross-sectional study in which less than 6 months' use of prednisolone at a median dose of 7.5 mg was associated with hypertension. In a German registry study, among patients who received doses of less than 7.5 mg for less than 6 months, there were higher rates of self-reported elevations in blood pressure.

The findings are at odds, however, with a recent matched-cohort study, which also used data from the Clinical Practice Research Datalink. That study found no association between GC use and hypertension.

GCs have come under increasing scrutiny in regard to several diseases. A study published this week found that even short-term courses of a few days' duration entail risks for serious adverse events.

Costello's group says that an estimate of GC-related incident hypertension in RA should allow more informed treatment decisions and that their findings highlight the ongoing need to monitor for and address this risk.

The study was supported by the Center for Epidemiology Versus Arthritis and by the National Institute for Health Research Manchester Biomedical Research Center. Coauthor Dixon has received consultancy fees from Google and Beyer unrelated to this study. Bhatt has disclosed no relevant financial relationships.

Rheumatol. Published online June 27, 2020. Full text

For more news, follow Medscape on Facebook, Twitter, Instagram, and YouTube.

More:
Steroids Linked to Increased Hypertension in RA - Medscape

Osteoarthritis is a degenerative joint disease that is the most common type of arthritis. Usually, it occurs among people of advanced age. But it can begin in middle age or even sooner, especially if theres been an injury to the joint.

While there are treatments available exercise, braces or canes, loss of excess weight, various pain relievers and anti-inflammatory medicines these are no cures, and none of the treatments are predictably effective. In fact, often they dont work at all, or help only a little. Injected steroids or synthetic lubricants can be tried as well. When all else fails, joint replacement surgery can be highly effective. In fact, about a million joint replacements (mostly knees and hips) are performed each year in the U.S.

So, its no surprise that people with osteoarthritis will try just about anything that seems reasonably safe if it might provide relief. My patients often ask about diet, including anti-inflammatory foods, antioxidants, low-gluten diets and many others. Theres little evidence that most of these dietary approaches work. When there is evidence, it usually demonstrates no consistent or clear benefit.

Thats why one study is noteworthy: It suggests that curcumin, a naturally occurring substance found in a common spice, might work for osteoarthritis.

In the study, researchers enrolled 139 people with symptoms of knee osteoarthritis. Their symptoms were at least moderately severe and required treatment with a nonsteroidal anti-inflammatory drug (NSAID). For one month, they were given the NSAID diclofenac (50 mg, twice daily) or curcumin (500 mg, three times daily).

Why curcumin? Its a naturally occurring substance, found in the spice turmeric, that has anti-inflammatory effects. Its use has been advocated for cardiovascular health, arthritis and a host of other conditions. However, well-designed studies of its health benefits are limited.

Heres what this study found:

Ready to start taking curcumin?

Not so fast. Its rare that a single study can change practice overnight, and this one is no exception. A number of factors give me pause:

Studies of this sort are vitally important in trying to understand whether dietary changes can be helpful for arthritis. While this new study provides support for curcumin as a treatment for osteoarthritis of the knee, Id like to see more and longer-term studies in osteoarthritis and other types of joint disease, as well as more extensive testing of its safety, before recommending it to my patients.

Go here to read the rest:
Curcumin for Arthritis: Does it Really Work? - Chicago Health